ArticleThe Journal of biological chemistry2005
Potent glycan inhibitors of myelin-associated glycoprotein enhance axon outgrowth in vitro.
Article in The Journal of biological chemistry, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 66 citations in OpenAlex.
- Molecular approaches for spinal cord injury treatment.Neural regeneration research · 2023Review
- Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- GM1 ganglioside prevents axonal regeneration inhibition and cognitive deficits in a mouse model of traumatic brain injury.Scientific reports · 2018Article
- Galectins: their network and roles in immunity/tumor growth control.Histochemistry and cell biology · 2017Review
- Restoring GM1 ganglioside expression ameliorates axonal outgrowth inhibition and cognitive impairments induced by blast traumatic brain injury.Scientific reports · 2017Article
- Sweet complementarity: the functional pairing of glycans with lectins.Cellular and molecular life sciences : CMLS · 2016Review
- Functional interplay between ganglioside GM1 and cross-linking galectin-1 induces axon-like neuritogenesis via integrin-based signaling and TRPC5-dependent Ca²⁺ influx.Journal of neurochemistry · 2016Article
- Determination of major sialylated N-glycans and identification of branched sialylated N-glycans that dynamically change their content during development in the mouse cerebral cortex.Glycoconjugate journal · 2014Article
- Sialic acids in the brain: gangliosides and polysialic acid in nervous system development, stability, disease, and regeneration.Physiological reviews · 2014Review
- High affinity sialoside ligands of myelin associated glycoprotein.Bioorganic & medicinal chemistry letters · 2011Article
- Glycosphingolipid functions.Cold Spring Harbor perspectives in biology · 2011Review
- Functionalization of electrospun fibers of poly(epsilon-caprolactone) with star shaped NCO-poly(ethylene glycol)-stat-poly(propylene glycol) for neuronal cell guidance.Journal of materials science. Materials in medicine · 2010Article
- Sialidase enhances recovery from spinal cord contusion injury.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Brain gangliosides in axon-myelin stability and axon regeneration.FEBS letters · 2010Review
- Gangliosides in cell recognition and membrane protein regulation.Current opinion in structural biology · 2009Review
- From carbohydrate leads to glycomimetic drugs.Nature reviews. Drug discovery · 2009Review
- Article
- Cell surface O-glycans limit Staphylococcus aureus adherence to corneal epithelial cells.Infection and immunity · 2008Article
- The chemical neurobiology of carbohydrates.Chemical reviews · 2008Review
- The inhibition site on myelin-associated glycoprotein is within Ig-domain 5 and is distinct from the sialic acid binding site.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Myelin-associated glycoprotein (MAG, Siglec-4) is one of several endogenous axon regeneration inhibitors that limit recovery from central nervous system injury and disease. Molecules that block such inhibitors may enhance axon regeneration and functional recovery. MAG, a member of the Siglec family of sialic acid-binding lectins, binds to sialoglycoconjugates on axons and particularly to gangliosides GD1a and GT1b, which may mediate some of the inhibitory effects of MAG. In a prior study, we identified potent monovalent sialoside inhibitors of MAG using a novel screening platform. In the current study, the most potent of these were tested for their ability to reverse MAG-mediated inhibition of axon outgrowth from rat cerebellar granule neurons in vitro. Monovalent sialoglycans enhanced axon regeneration in proportion to their MAG binding affinities. The most potent glycoside was disialyl T antigen (NeuAcalpha2-3Galbeta1-3[NeuAcalpha2-6]GalNAc-R), followed by 3-sialyl T antigen (NeuAcalpha2-3Galbeta1-3GalNAc-R), structures expressed on O-linked glycoproteins as well as on gangliosides. Prior studies indicated that blocking gangliosides reversed MAG inhibition. In the current study, blocking O-linked glycoprotein sialylation with benzyl-alpha-GalNAc had no effect. The ability to reverse MAG inhibition with monovalent glycosides encourages further exploration of glycans and glycan mimetics as blockers of MAG-mediated axon outgrowth inhibition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.